SecBot SecBot
8-K ·Filed May 13, 2026

FATE

FATE THERAPEUTICS INC
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-220691
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming clinical data readouts at EULAR (June 2026) and ASCO (June 2026) for FT819 and FT836, respectively. The CDRP selection and RMAT designation provide regulatory tailwinds, but the stock remains binary on Phase 2 data. The extended cash runway removes near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.14
T+0 close · May 13, 2026 · via day close
Latest settled
+30.84%
T+60 · $2.80
Vs SPY
+26.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $2.14entry
  2. T+1 · 6mo ago −11.21%α −11.99% · $1.90
  3. T+5 · 6mo ago −11.68%α −10.52% · $1.89
  4. T+20 · 5mo ago −7.94%α −7.33% · $1.97
  5. T+60 · 3mo ago +30.84%α +26.40% · $2.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in Q1 2025, and revenue of $1.3M from its Ono collaboration. The key catalysts are regulatory and clinical: FT819 was selected for the FDA's CDRP program, the Phase 2 RECLAIM-LN trial is on track for H2 2026, and the operating runway was extended into 2028 with $174.8M in cash. However, the company remains a pre-revenue clinical-stage biotech with no approved products and a net loss of $31.2M for the quarter.

Key Financial Metrics

EPS
−$0.26
est −$0.29 · +10.3%
Revenue
$1.3M
est $1.5M · -13.3% · -20.2% YoY
Rating
in line

Key Facts

  • Cash, cash equivalents, and investments of $174.8M as of March 31, 2026, providing runway into 2028
  • Net loss of $31.2M for Q1 2026, improved from $37.6M loss in Q1 2025
  • Revenue of $1.3M from Ono Pharmaceutical collaboration, down from $1.6M in Q1 2025
  • FT819 selected for FDA's CDRP program, potentially accelerating regulatory pathway
  • Phase 2 RECLAIM-LN trial for lupus nephritis on track to initiate in H2 2026
  • FT819 Phase 1 enrollment at 27 patients across 18 global sites as of May 5, 2026
  • FT836 Phase 1 solid tumor study has treated 9 patients; FT839 IND submission planned for H2 2026
  • Operating expenses reduced 20% YoY to $34.3M in Q1 2026
  • Total operating expenses of $34.3M included $3.9M non-cash stock-based compensation

Financial Impact

No material financial impact from this filing; company is pre-revenue with $174.8M cash runway into 2028

cash positionoperating expensesnet loss

Risk Factors

  • Clinical trial failure or delay in RECLAIM-LN or other programs
  • Regulatory setbacks despite CDRP and RMAT designations
  • Cash burn rate of ~$10.4M/month may require future capital raises
  • Competition from approved CAR-T therapies and other autoimmune treatments
  • Dependence on Ono collaboration for revenue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-220691
Document: fate-20260513.htm0001193125-26-220691
Document: 0001193125-26-220691-index-headers.html0001193125-26-220691
Document: 0001193125-26-220691-index.html0001193125-26-220691
Document: 0001193125-26-220691.txt0001193125-26-220691
8-K Data (Synthetic)0001193125-26-220691

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026